BIRC5 and glioma: Concerning a possible use of CBX in cancer, it has been shown that CBX inhibits the expression of the apoptosis-inhibitor-protein BIRC5/survivin and thereby triggers apoptosis in K562 leukemic cells [46] and enhances TRAIL-induced apoptosis in human glioma [47].